On December 1, 2015 ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, reported the presentation of new preclinical data with the Company’s experimental therapies IMGN529 and IMGN779 to be made at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting to be held December 5-8, 2015 in Orlando, FL (Press release, ImmunoGen, DEC 1, 2015, View Source [SID:1234508374]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ImmunoGen is advancing experimental therapies expected to make a meaningful difference for patients with cancer, and we believe the preclinical data being presented at ASH (Free ASH Whitepaper) with our IMGN529 and IMGN779 help demonstrate the potential significance of these programs," said Dr. Charles Morris, Executive Vice President and Chief Development Officer. "In preclinical assessments, IMGN529 demonstrates marked synergy with rituximab – a widely used therapy for non-Hodgkin lymphoma – which informed our decision to assess this combination clinically. The IMGN779 data being reported relate to its novel mechanism of action, which we believe could help patients with acute myeloid leukemia, and we expect to start clinical testing of this experimental therapy in early 2016."
In addition to these data presentations on ImmunoGen’s wholly owned compounds, clinical data will be presented with Sanofi’s CD38-targeting antibody isatuximab (SAR650984), which was developed in a research collaboration with ImmunoGen.
Title: "IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergystic Activity with Rituximab in Non-Hodgkin Lymphona (NHL) Models"
Poster session #625: Saturday, Dec. 5, 5:30-7:30 pm ET. Abstract #1548.
Title: "IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells"
Poster session #616: Saturday, Dec. 5, 5:30-7:30 pm ET. Abstract #1366.
Title: "A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma"
Oral presentation #653: Mon., Dec. 7, 8:00 am. Abstract #509.
Additional information can be found at www.hematology.org, including abstracts.